Tech in your toilet: OutSense raises $2.2 million for device that tests poo for health risks
Attaching its IoT device to a toilet bowl, bathroom visitors can help catch cancers and other diseases, company aims to create the world’s largest database of human waste
Currently, funds will be spent on completing the design of its product and expanding its medical trials with the hope of securing FDA-approval next year. Israel’s Meir Medical Center in Israel has already validated the detection of hidden blood in the stool, highlighting a 90% accuracy rate in spotting potential diseases. Each year, more than 700,000 people die from colorectal cancer - a number that can be dramatically reduced if testing can be achieved once, maybe even twice, a day.
Yfat Scialom, CEO of OutSense. Photo: OutSense “Our technology allows users and patients to have their excretions scanned automatically and immediately receive actionable insights based on the underlying chemical and physical composition,” explained Yfat Scialom, CEO of OutSense. “Besides the medical impact, this solution also gives people new ways to improve their wellness, improve compliance with medications, and monitor diets and personal nutritional needs.”
OutSense is planning its splash into the market by focusing its efforts on remote monitoring of the elderly, a fast-growing market due to Covid-19 and increased lockdowns around the world. Its product will be able to clip onto any standard toilet bowl and uses multi-spectral optical sensors and an autonomous Wi-Fi receiver. Eventually, it hopes to create the world’s largest database of human waste.
The OutSense device can easily clip onto any toilet bowl. Photo: OutSense “This is especially crucial in colorectal cancer and other conditions which often go undiagnosed,” added Scialom. Eventually, the technology will be able to help visitors detect the onset of Covid-19, as well as for personalized care, general biofeedback, fine-tuning of drug dosage, or personalized nutrition for weight control.
OutSense was founded in 2016 in Or Yehuda, Israel. It was part of the Life Sciences’ Incentive Incubator, which is owned by Peregrine Ventures, in partnership with the Israel Innovation Authority.
